Frequency of Circulating Tregs with Demethylated FOXP3 Intron 1 in Melanoma Patients Receiving Tumor Vaccines and Potentially Treg-Depleting Agents
暂无分享,去创建一个
C. Punt | P. Coulie | G. Adema | G. Schuler | S. Lucas | C. Castelli | L. Rivoltini | B. Schuler-Thurner | J. Stockis | C. Huygens | I. D. de Vries | J. Jacobs
[1] C. Figdor,et al. Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients , 2010, Clinical Cancer Research.
[2] Dan R. Littman,et al. Th17 and Regulatory T Cells in Mediating and Restraining Inflammation , 2010, Cell.
[3] A. Rudensky,et al. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate , 2010, Nature.
[4] R. Vonderheide,et al. Clinical Use of Anti‐CD25 Antibody Daclizumab to Enhance Immune Responses to Tumor Antigen Vaccination by Targeting Regulatory T cells , 2009, Annals of the New York Academy of Sciences.
[5] G. Schuler,et al. The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells. , 2009, Cancer research.
[6] P. Coulie,et al. Comparison of stable human Treg and Th clones by transcriptional profiling , 2009, European journal of immunology.
[7] Fabian Model,et al. Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. , 2009, Cancer research.
[8] D. Niedzwiecki,et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. , 2008, Blood.
[9] Dianne Miller,et al. Transient T-cell depletion causes regression of melanoma metastases , 2008 .
[10] E. Tartour,et al. Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities. , 2008, Cancer research.
[11] C. Figdor,et al. Dendritic cell vaccines in melanoma: from promise to proof? , 2008, Critical reviews in oncology/hematology.
[12] K. McMasters,et al. Transient T cell depletion causes regression of melanoma metastases , 2008, Journal of Translational Medicine.
[13] B. Chauffert,et al. Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes , 2007, Clinical and experimental immunology.
[14] M. Colombo,et al. Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy , 2007, Nature Reviews Cancer.
[15] I. Türbachova,et al. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3+ conventional T cells , 2007, European journal of immunology.
[16] M. Banerjee,et al. Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. , 2007, Cancer research.
[17] E. Shevach,et al. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. , 2007, Blood.
[18] A. Enk,et al. Depletion of CD4+CD25+ human regulatory T cells in vivo: Kinetics of Treg depletion and alterations in immune functions in vivo and in vitro , 2007, International journal of cancer.
[19] Edgar Schmitt,et al. Epigenetic Control of the foxp3 Locus in Regulatory T Cells , 2007, PLoS biology.
[20] B. Chauffert,et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients , 2007, Cancer Immunology, Immunotherapy.
[21] A. Rudensky,et al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[22] S. Ziegler. FOXP3: of mice and men. , 2006, Annual review of immunology.
[23] Thierry Boon,et al. Human T cell responses against melanoma. , 2006, Annual review of immunology.
[24] S. Rosenberg,et al. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. , 2006, Blood.
[25] S. Kim-Schulze,et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] E. Gilboa,et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. , 2005, The Journal of clinical investigation.
[27] S. Rosenberg,et al. Inability of a Fusion Protein of IL-2 and Diphtheria Toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to Eliminate Regulatory T Lymphocytes in Patients With Melanoma , 2005, Journal of immunotherapy.
[28] J. Berzofsky,et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells , 2005, Nature Medicine.
[29] P. Coulie,et al. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens , 2005, The Journal of experimental medicine.
[30] P. Coulie,et al. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen , 2005, The Journal of experimental medicine.
[31] B. Chauffert,et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative , 2004, European journal of immunology.
[32] C. Figdor,et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[33] G. Schuler,et al. Rapid Induction of Tumor-specific Type 1 T Helper Cells in Metastatic Melanoma Patients by Vaccination with Mature, Cryopreserved, Peptide-loaded Monocyte-derived Dendritic Cells , 2002, The Journal of experimental medicine.
[34] R. North. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells , 1982, The Journal of experimental medicine.